Search the GHTC website

Global health R&D delivers for Kentucky

US government investment in global health R&D has delivered

$62.3 million
to Kentucky research institutions
800+ new jobs
for Kentucky
Kentucky's top USG-funded global health R&D institutions

Kentucky's top USG-funded global health R&D institutions

University of Louisville
$36.8 million
University of Kentucky
$16.2 million
MosquitoMate Inc.
$5.3 million
$1.5 million
$1.1 million
Vindico Pharmaceuticals*
$773 thousand
Owensboro Health (formerly Owensboro Medical Health System Inc.)
$607 thousand

Kentucky's top areas of global health R&D by USG funding

Neglected tropical diseases
Helminth infections (Worms & Flukes)
Kinetoplastid diseases
Arenaviral hemorrhagic fevers (including Lassa fever)
Bunyaviral diseases (including CCHF, RVF, SFTS)
Filoviral diseases (including Ebola, Marburg)
Multi-disease/health area R&D
Other coronaviruses (including MERS, SARS)
Reproductive health
Salmonella infections
Global health R&D at work in Kentucky

The University of Kentucky leads an international team of researchers that has discovered a promising, fast-acting antimalarial compound. It is one of the first in a new class of antimalarial compounds to reach clinical trials. Decades of hard-fought progress against malaria is now threatened by rising drug resistance. For example, up to 60 percent of malaria patients in central Asia have a drug-resistant form of the disease—underscoring the urgent need to develop new treatments before existing drugs become ineffective. In partnership with the nonprofit Medicines for Malaria Venture, the Kentucky team is continuing research to advance this discovery to market.

  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: PMI